Ask the research

Based on ARN's corpus, human trial data are available for the combination of dasatinib plus quercetin, as well as for fisetin12.

• Dasatinib plus quercetin: A small, randomized, double-blind, placebo-controlled phase-2 trial evaluated this regimen in 31 patients with fibrotic metabolic dysfunction-associated steatohepatitis (MASH)1. Intermittent therapy using 100 mg of dasatinib and 1,000 mg of quercetin daily significantly improved liver fibrosis without disease worsening (47% versus 7% on placebo) and lowered markers of cellular senescence, though self-limiting side effects occurred in 82% of treated participants compared to 43% receiving placebo1.
• Fisetin: A systematic review identified four completed clinical trials with available results2. However, the evidence remains limited, heterogeneous, and inconclusive, with some studies showing improvements in inflammatory or metabolic markers while others demonstrated no meaningful benefit2. The interpretation of these trials is hampered by small cohorts, multimodal interventions, and exploratory or uncontrolled designs2.

Other approaches mentioned in the sources, such as autologous cytokine-induced natural killer cells, have not yet been evaluated in human trials for senescent cell clearance or biological aging endpoints3.